*It may take a few minutes for the email to arrive.
**Be sure to check your spam/junk folder.
Vyleesi helps treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
The U.S. Food and Drug Administration (FDA) has approved Vyleesi (bremelanotide) for the treatment of acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. This approval offers new hope for women experiencing low sexual desire that leads to marked distress, and who are seeking an effective pharmacological option.
Vyleesi acts on melanocortin receptors, although the exact mechanism by which it enhances sexual desire and alleviates distress is still under investigation. Unlike daily treatments, Vyleesi is used as needed by administering an injection under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity. This allows users to manage the timing based on their experiences of the benefits and any side effects, such as nausea.
Vyleesi is specifically designed for premenopausal women with acquired, generalized HSDD. This condition is characterized by a significant decrease in sexual desire that is not attributed to medical or psychiatric conditions, relationship issues, or the use of other medications or substances. It affects women who previously had no problems with sexual desire and occurs regardless of the type of sexual activity, the situation, or the partner. Common symptoms associated with HSDD are an absence of sexual fantasies, thoughts, and/or desire for or receptivity to sexual activity.
Vyleesi represents a significant advancement in the treatment options available for premenopausal women suffering from HSDD. It provides a needed alternative for those who can benefit from pharmacologic treatment to manage this challenging condition effectively. As with any medication, women interested in Vyleesi should discuss it with their healthcare provider to ensure it is the appropriate treatment based on their health status and medical history.
Reference:
Vyleesi [package insert]. Waltham, MA: AMAG Pharmaceutics, Inc.; 2019.
There is no reason to suffer. Get help today. Find a menopause-specific doctor or healthcare expert near you to help support your perimenopause and menopause journey.